Vertex Pharmaceuticals Incorporated data readout from a phase 3 program, using VX-548 for the treatment of patients with acute pain, could be released by the 1st half of 2024. Proof of concept, using ...
CEO David DeStefano highlighted Vertex's strong start to 2025, reporting $177.1 million in revenue, a 12.9% year-over-year increase, supported by 14.4% growth in subscription revenue and 29.6% growth ...
After posting a disappointing forecast for 2017, Vertex is consolidating its R&D operations, according to a securities filing. The company plans to close a site in Canada, cutting 70 jobs, and trimmed ...
BMO Capital Markets analyst Daniel Jester reiterated the Market Perform rating on Vertex, Inc. (NASDAQ:VERX), raising the price target to $28 from $24. Investors rewarded the consistent execution ...
On the heels of Vertex Pharmaceuticals' ($VRTX) big news last week about changing CEOs next year, FierceBiotech chatted with both current chief executive Matt Emmens ...
Zacks.com on MSN
Vertex Up 25% YTD: Should You Buy, Sell or Hold the Stock?
Vertex Pharmaceuticals Incorporated VRTX stock has plunged 25.3% this year so far against the industry’s 5.4% increase. Image ...
3D Systems, a 3D printer and additive manufacturing system company, said it will acquire Vertex-Global Holding in a deal that highlights how market players are increasingly targeting industries for ...
Vertex Ventures, which is backed by Singapore state investment firm Temasek Holdings and closed its fifth India and Southeast Asia-focused fund at $541 million (about Rs 4500 crore) late last year, ...
Vertex Pharmaceuticals opened its new San Diego research center Monday, starting a new chapter in a decades-long quest to not only treat but cure cystic fibrosis. In 18 years, three drugs for the lung ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback